Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer

NCT00499512 | Unknown

• 1 other identifier: 2004-0283
• Study Type: observational
• Target: 115
• Locations: 1 country
• Sites: 4

Brief Summary

The goal of this psychosocial research study is to examine and explain the influence of spirituality on patients with ovarian, primary peritoneal or fallopian tube cancer.

Conditions

Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer

Keywords

Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer; Spirituality; Religion; Quality of Life; Questionnaire; Survey

Outcome Measures

Primary Outcomes (1)

• Patient Response to Questionnaire (Spiritual assessments)

  From diagnosis to completion of primary therapy and to 1 year after completion of primary therapy.

Study Arms (1)

Spirituality Questionnaire

Patients with newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer.

Behavioral: Questionnaire

Interventions

Questionnaire BEHAVIORAL

Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).

Also known as: Survey

Spirituality Questionnaire

Eligibility Criteria

• Sex: female
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with newly diagnosed ovarian, primary peritoneal or fallopian tube cancer.

You may qualify if:

• All newly diag Stage II-IV ovarian, primary peritoneal or fallopian tube ca patients prior to initiating C2 of chemo. (A pt with synchronous primary endometrial ca, or HX of primary endometrial ca, can participate if these conditions are met: endometrial ca stage not greater than I-B; no more than superficial myometrial invasion, w/o vascular or lymphatic invasion; no poorly differentiated subtypes, incl papillary serous, clear cell or other FIGO G3 lesions; no add'l tx other than req for ovarian, prim. peritoneal or fallopian tube ca is recommended.)
• Patients who receive neoadjuvant chemotherapy (prior to a planned interval cytoreduction for a suspected ovarian, primary peritoneal or fallopian tube cancer) are also eligible as long as there is pathologic confirmation of cancer prior to study enrollment.

You may not qualify if:

• Patients who do not speak or read English or Spanish.
• Patients with Stage I ovarian, primary peritoneal or fallopian tube cancer or patients with tumors of low malignant potential or borderline tumors.
• Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, who do not meet the criteria listed above.

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead
• The Blanton Davis Ovarian Cancer Research Program: collaborator

Study Sites (4)

Lyndon B. Johnson General Hospital

Houston, Texas, 77030, United States

Location

St. Luke's Episcopal Hospital

Houston, Texas, 77030, United States

Location

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

The Woman's Hospital of Texas

Houston, Texas, 77054, United States

Location

Related Links

• University of Texas MD Anderson Cancer Center Website

MeSH Terms

Conditions

Ovarian Neoplasms; Fallopian Tube Neoplasms

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Fallopian Tube Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Lois M. Ramondetta, MD

  M.D. Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 10, 2007
• First Posted: July 11, 2007
• Study Start: August 10, 2005
• Primary Completion: August 31, 2020
• Study Completion: August 31, 2020
• Last Updated: January 10, 2020

Record last verified: 2020-01

Locations

US (4)